Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|July 8, 2022
Daily Medication Pearl: Tildrakizumab-asmn (Ilumya)
Author(s)Saro Arakelians, PharmD
Tildrakizumab-asmn (Ilumya) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Advertisement
Medication Pearl of the Day: Tildrakizumab-asmn (Ilumya)
Indication: Tildrakizumab-asmn (Ilumya) is an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Insight:
- Dosing: Injection 100 mg/mL solution in a single-dose prefilled syringe.
- Dosage forms: Recommended dose is 100 mg at weeks 0, 4, and every 12 weeks thereafter.
- Adverse events: Most common (≥1%) adverse reactions associated with tildrakizumab treatment are upper respiratory infections, injection site reactions, and diarrhea.
- Mechanism of action: Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.
Source:
Advertisement
Related to this article
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
3
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
4
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
5